Q32 Bio Inc. reported a net loss of $8.9 million, or $0.26 per share, for the quarter ended September 30, 2026, compared to a $7.4 million loss in the prior-year period. The company held cash and cash equivalents of $289.6 million as of September 30, 2026, which management believes provides sufficient runway through topline Phase 3 results from its planned registration-directed program for bempikibart in severe alopecia areata. Q32 Bio also announced the appointment of José Trevejo as Chief Medical Officer and Ellie Hershberger as Chief Development Officer. The company is expected to initiate a registration-directed clinical trial in the first half of 2027 following regulatory discussions this quarter.
